GEORGE DIVIDIS

Dr. GEORGE DIVIDIS


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMarino Basha
Marino Basha
ESEvdoxia Stavropoulou
Evdoxia Stavropoulou
ANAnastasia Nikolaidou
Anastasia Nikolaidou
GDGEORGE DIVIDIS
GEORGE DIVIDIS
EPEmmanouela Peteinidou
Emmanouela Peteinidou
VKVasileios Kamperidis
Vasileios Kamperidis
Obesity is a current pandemic that sets all affected individuals at risk of heart failure (HF), and the majority of them will develop the clinical syndrome of HF with preserved ejection fraction (HFpEF). The diagnosis of HFpEF is challenging as it is based on the detection of subtle functional and structural remodeling of the heart that leads to diastolic dysfunction with increased left ventricular (LV) filling pressures and raised natriuretic peptides (NPs). The accurate diagnosis of HFpEF is even more challenging in patients who are obese, since the echocardiographic imaging quality may be suboptimal, the parameters for the evaluation of cardiac structure are indexed to the body surface area (BSA) and thus may underestimate the severity of the remodeling, and the NPs in patients who are obese have a lower normal threshold. Moreover, patients who are obese are prone to atrial fibrillation (AF) and pulmonary hypertension (PH), making the evaluation of diastolic dysfunction more strenuous. The current review aims to offer insights on the accurate diagnosis of HFpEF in patients who are obese in different clinical scenarios—patients who are obese in different clinical scenarios—such as in sinus rhythm, in atrial fibrillation, and in the case of pulmonary hypertension—by applying multimodality imaging and clinical diagnostic algorithms.

9 December 2022 in Cureus
Verified
Journal Article
Open access
GDGEORGE DIVIDIS
GEORGE DIVIDIS
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
IKIoannis Karageorgiou
Ioannis Karageorgiou
GKGeorgios Kotronis
Georgios Kotronis
Remdesivir is an antiviral agent used as supportive care in adults with SARS-COV2-induced pneumonia. We report a case of an 81-year-old patient who developed hepatocellular acute liver injury 48 hours after initiating remdesivir. During the investigation, other causes of hepatotoxicity were excluded. A decrease in transaminases and international normalized ratio (INR) was observed 24 hours after cessation of remdesivir. An abdominal CT demonstrated hepatic congestion, retrograde hepatic venous opacification shortly after intravenous contrast injection, and dilatation of hepatic veins and inferior vena cava. We suggest congestive hepatopathy secondary to remdesivir as a possible component of liver injury.

3 August 2024 in Cureus
Verified
Journal Article
Open access
GDGEORGE DIVIDIS
GEORGE DIVIDIS
DPDimitrios Pallas
Dimitrios Pallas
IKIoannis Karageorgiou
Ioannis Karageorgiou
FLFoteini Lazaridou
Foteini Lazaridou
A 3.5 cm diameter descending aorta focal aneurysm was incidentally found when a computed tomography (CT) was conducted due to persistent pyrexia in an 85-year-old woman hospitalized for a non-obstructive urinary tract infection. Ten days later, whilst fever subsided and inflammation markers decreased, she became hypoxic. CT revealed an aortic intramural hematoma (Stanford type B) increasing the diameter of the thoracic aorta aneurysm to 6.5 cm. A thoracic endovascular aortic repair (TEVAR) surgery was performed. Seven days after the operation she developed respiratory and hemodynamic compromise. CT depicted further enlargement of the aortic intramural hematoma, increasing the aortic diameter to 8 cm. Transthoracic echocardiography provided valuable information showing extrinsic compression of the left atrium and left ventricle inflow obstruction provoking obstructive shock.